Anixa Biosciences (NASDAQ:ANIX) Earns “Buy” Rating from D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $10.00 target price on the stock. D. Boral Capital’s price target would indicate a potential upside of 287.60% from the company’s previous close.

Several other analysts also recently issued reports on ANIX. Maxim Group assumed coverage on Anixa Biosciences in a report on Friday, March 21st. They issued a “buy” rating and a $10.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, March 25th.

Anixa Biosciences Price Performance

Shares of ANIX opened at $2.58 on Thursday. The stock has a market capitalization of $83.07 million, a PE ratio of -6.62 and a beta of 0.52. The business’s fifty day moving average price is $2.92 and its 200 day moving average price is $2.95. Anixa Biosciences has a 12-month low of $2.07 and a 12-month high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). As a group, research analysts anticipate that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Transactions at Anixa Biosciences

In related news, CEO Amit Kumar acquired 43,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were acquired at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the purchase, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The stock was bought at an average price of $2.57 per share, with a total value of $25,700.00. Following the transaction, the director now directly owns 922,334 shares in the company, valued at $2,370,398.38. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 75,289 shares of company stock worth $177,021. Company insiders own 25.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Focus Partners Wealth acquired a new stake in Anixa Biosciences in the fourth quarter worth approximately $162,000. Jane Street Group LLC acquired a new stake in shares of Anixa Biosciences in the fourth quarter valued at $67,000. Prosperity Wealth Management Inc. bought a new position in Anixa Biosciences during the fourth quarter valued at about $54,000. Westside Investment Management Inc. boosted its stake in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in Anixa Biosciences by 37.2% during the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock worth $100,000 after acquiring an additional 11,633 shares during the period. 29.13% of the stock is currently owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.